Compare · CAPR vs NVO
CAPR vs NVO
Side-by-side comparison of Capricor Therapeutics Inc. (CAPR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAPR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 124.0x CAPR ($1.55B).
- Over the past year, CAPR is up 99.5% and NVO is down 44.4% - CAPR leads by 143.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for CAPR).
- NVO has more recent analyst coverage (25 ratings vs 9 for CAPR).
- Company
- Capricor Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $26.66-0.17%
- $41.95-2.31%
- Market cap
- $1.55B
- $191.82B
- 1M return
- -21.39%
- -8.38%
- 1Y return
- +99.51%
- -44.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 9
- 25
Capricor Therapeutics Inc.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CAPR
- Capricor Therapeutics to Present at Upcoming Investor Conferences
- SEC Form 4 filed by CHIEF COMMERCIAL OFFICER Maurer Michael T
- SEC Form 3 filed by new insider Maurer Michael T
- CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 3,000 shares at a strike of $1.39, increasing direct ownership by 36% to 11,223 units (SEC Form 4)
- Director Litvack Frank exercised 3,937 shares at a strike of $1.39, increasing direct ownership by 3% to 133,776 units (SEC Form 4)
- SEC Form 10-Q filed by Capricor Therapeutics Inc.
- Capricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Capricor Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- EVP, GENERAL COUNSEL Krasney Karen exercised 25,000 shares at a strike of $3.18 and sold $792,548 worth of shares (25,000 units at $31.70) as part of a pre-agreed trading plan (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care